---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-24-000060"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2024-07-25T23:59:59+00:00"
generated_at: "2026-05-31T16:09:17.049324+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q2 net sales miss; slashes FY 2024 EPS guidance by over $1.20

## Summary
- Q2 net sales $702.1M, down 6.9% YoY; reported diluted EPS $1.51 vs $2.06; adj. EPS $1.52 vs $2.11.
- Proprietary Products sales fell 9.4% to $559.7M; customer destocking continues, especially in Generics.
- FY 2024 net sales guidance cut to $2.87-2.90B from $3.00-3.025B; adj. EPS lowered to $6.35-6.65 from $7.63-7.88.
- First-half free cash flow fell 38.3% to $92.4M; company repurchased 1.24M shares for $454.1M at avg $366.53.
- Management expects organic growth to return in Q4 and 2025; capex guidance raised to $375M.

## SEC filing metadata
- accession: 0000105770-24-000060
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2024-07-25T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577024000060/0000105770-24-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577024000060/wst-20240725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-24-000060
- JSON: https://secwatch.observer/filing/0000105770-24-000060.json
- Plain text: https://secwatch.observer/filing/0000105770-24-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.